Assoc. Prof. ISIK G. YULUG
Dr. Isik G. Yulug is Associate Professor at Bilkent University, Molecular Biology and Genetics. She has been the Chair of the Department between 2014-2017. Dr. Yulug graduated from Hacettepe University, Faculty of Science, Department of Biology, Ankara, Turkey. She received her master’s degree from Hacettepe University, Faculty of Medicine, Medical Biology Department in 1990. She then earned her PhD degree in molecular genetics at University of London, the Imperial College of Science, Technology and Medicine in 1995. She worked at University of London, Ludwig Cancer Institute, London and M.D. Anderson Cancer Research Center. She was awarded with NATO PhD fellowship by TUBITAK. She is a recipient of Lawley Scholarship by University of London, the Best Scientific Work Award of the World Society for Breast Health and the L’Oreal-UNESCO Women in Science Award. She joined to the Bilkent University in 1996. She acted as assistant chair between 2001-2007 and as a deputy chair in 2007-2008. She has been the member of Science Faculty Board since 2002, member of the Board of directors in Graduate School of Engineering and Science, Bilkent University since 2012. She served as Council Member in European Association for Cancer Research and has been representing Turkey in the council for four years. She worked as an Elected Steering Committee Member for the Research Networking Program on Frontiers of Functional Genomics in European Science Foundation since for four years. She is currently serving as a member of UNESCO Bioethics Committee member in Turkey. Her group has concentrated working on the identification, expression profiling, and epigenetic mechanisms of the genes involved in initiation and progression of human malignancies especially in breast cancer. Her articles published in citation index journals received over 1500 citations.
Dean of Faculty of Science
Prof. Dr. H. TAYFUN OZCELIK
Dr. Özçelik graduated from İstanbul University, İstanbul Medical School in 1986. He completed his postdoctoral work in physiology at the Ludwig-Maximilians-Universität München, and in human genetics at the Yale University School of Medicine and at the Howard Hughes Medical Institute, Stanford University School of Medicine. He returned to Turkey in 1992 as assistant professor and founding head of the Department of Genetics at DETAM, Istanbul University. In 1995, he joined the Department of Molecular Biology and Genetics at Bilkent University. He was named associate professor in 1994 and professor in 2004. He was appointed as the Dean of the Faculty of Science in 2012. His research focuses on inherited phenotypes in humans. He contributed to the mapping of genes to human and mouse chromosomes, and identified SNRPN in Prader-Willi syndrome, PMP22 in Charcot-Marie-Tooth disease Type IA, PHKA2 in X-linked liver glycogenesis, MLH1 in MLH1-deficiency, VLDLR & WDR81 & ATP8A2 in cerebellar hypoplasia associated with quadrupedal gait in humans, HTRA2 in Parkinson’s disease and essential tremors, and RAD21 in chronic intestinal pseudo-obstruction. He introduced DNA-based individual identification to the Turkish judiciary system and also led diagnostic genetics laboratories both at Istanbul and Bilkent Universities. Currently, he works on the complex phenotypes of obesity and polycystic ovarian syndrome in collaboration with Rockefeller University. Dr. Özçelik is a member of the Turkish Academy of Sciences serving as a councilor, board member and education committee chair of the European Society of Human Genetics, program committee member of the American Society of Human Genetics, and past-president of the Turkish Society of Medical Genetics. He received the TÜBİTAK Young investigator Award in 1996, Bayındır Medical Award in 2006, and TÜBİTAK Science Award in 2012.
Prof. Dr. IHSAN GURSEL
Prof. Ihsan Gursel received his PhD from the Middle East Technical University (METU, Ankara, Turkey) in 1995. He is currently pursuing research on immunology, nanomedicine, biomaterials, and tries to develop more effective treatment modalities to cancer and infectious diseases with an interdisciplinary approach. Before joining Bilkent University, Dr. Gursel spent more than ten years of his career working in different research and government institutes, including The School of Pharmacy, University College London (1993-1994) and METU, Department of Biological Sciences (1995-1998) and lastly US Food and Drug Administration, Center for Biologics Evaluation and Research (1998-2005) as a senior scientist. During his last post in US FDA, Dr. Gursel in addition to his regulatory duties, he engaged in research activities aiming to understand the immunomodulatory properties of DNA and other nucleic acid molecules on innate immune system. Currently, his Lab tries to harness nucleic acid ligands for immunotherapy of cancer, and infectious diseases, in addition to utilize them to down-regulate auto-immune and auto-inflammatory symptoms. He has organized several national and international meetings and workshops on immunology and nanobiosciences. His cutting-edge research activities led him to issue several international patents as a co-inventor. Most of his articles published in prestigious journals such as Science Translational Medicine, Journal of Experimental Medicine, Journal of Immunology, Journal of Biological Chemistry, Infection and Immunity, Allergy, and Biomaterials. He has received over 3450 citations (h-Factor: 29). He is a full-member of the Academy of Sciences, and executive committee member of the Turkish Immunology Society. He is also a co-founder of several national/international societies. Dr. Gursel is married and has a son. Among his special interests, Dr. Gursel likes to read history and autobiography books and listens to jazz, classical music and opera.
Assoc. Prof. OZLEN KONU
Dr. Ozlen Konu graduated from METU in 1987 with a B.S. degree in Biological Sciences. Dr. Konu pursued her graduate studies in the Biology Department at Texas Tech University, and received her M.S. and Ph.D. degrees in 1992 and 1999, respectively. She was a postdoctoral research fellow at the University of Memphis at Tennessee during 2000-2002. Since September 2002, she is a faculty member at the Dept. Molecular Biology and Genetics, Bilkent University. Dr. Konu’s research interests include gene expression data analysis and meta-analysis with respect to cholinergic signaling as it applies to addiction and cancer, and comparative expression profiling using zebrafish model.
Assoc. Prof. ALİ OSMAY GÜRE
Associate Professor at Bilkent University, Department of Molecular Biology and Genetics, Ankara, Turkey (since 2006). Obtained his MD degree in 1988 from the University of Ankara, and a PhD in immunology from Cornell University Graduate School of Medical Sciences, USA, in 1995. Worked as an Assistant Member at the Ludwig Institute for Cancer Research - NYC branch (2000-2006) after completing a post-doctoral fellowship with Lloyd J. Old at the Memorial Sloan Kettering Cancer Center in New York City (1995-2000). His initial work focused on the discovery of tumor antigens and in particular the utilization of autologous immune responses against these as diagnostic and prognostic markers. He is thus, a co-inventor in 22 international patents related to tumor antigens/biomarkers. His more recent work focuses on those mechanisms leading to expression of cancer-testis antigen genes which function as biomarkers of ectopic hypomethylation in cancer, and the identification of biomarkers of diagnosis, prognosis and chemosensitivity. His work is currently supported by 3 grants from the Turkish Scientific and Medical Council. He co-authored 40 manuscripts which received over 5500 citations.
Asst. Prof. EBRU ERBAY
Ebru Erbay is an Assistant Professor in the Department of Molecular Biology and Genetics in Bilkent University in Ankara, Turkey since 2010 and serves as Adjunct Professor in the Institute for Cardiovascular Prevention at the Ludwig Maximillians University in Munich, Germany as of 2016. She received MD degree from Ankara University Faculty of Medicine and PhD in Cell and Structural Biology from the University of Illinois, Urbana-Champaign. During her PhD studies she discovered the essential role of mTOR in myogenesis. Dr. Erbay completed her postdoctoral training with Prof. Gökhan Hotamışlıgil at Harvard University, School of Public Health where she demonstrated the therapeutic potential of targeting endoplasmic reticulum stress in cardiovascular disease. Dr. Erbay has been honored for her work by her election to the Turkish Academy of Science Young Investigator Program (TUBA-GEBIP), received NIH’s Ruth Kirschstein Research Service Award, American Heart predoctoral fellowship, Proctor & Gamble thesis research award and graduated with high honors from Ankara University Medical School. Her current research focus is at the intersection of nutrient-sensitive, inflammatory and stress pathways in the context of metabolic diseases. Dr. Erbay is the first time recipient of the prestigious European Research Commission (ERC) Starting Grant in Life Sciences awarded to a researcher in Turkey. Her research program at Bilkent University is generously funded by additional grants from European Molecular Biology Organization (EMBO), Marie Curie Reintegration, Turkey/Germany Bilateral Funding Scheme (TUBITAK/BMBF) and the International COST Action (TUBITAK) grants. She also served as an associate advisor to the Science Translational Medicine. Her twenty publications received more than 1300 citations and her review on metainflammation was chosen a classic only after 5 years by Forschende Komplementarmedizin.
Asst. Prof. ÖZGÜR ŞAHİN
Dr. Özgür Şahin graduated from the Department of Molecular Biology and Genetics at Middle East Technical University in 2003. He then earned his Ph.D. degree in cancer systems biology at German Cancer Research Center (DKFZ) and the University of Heidelberg in 2008. He held positions as a group leader in the Division of Molecular Genome Analysis at DKFZ and as research faculty in the Department of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center (MDACC). He is a recipient of the MDACC Specialized Program of Research Excellence from the USA, and the Wilhelm Sander Foundation Grant in Cancer Research from Germany. Since September 2013, he is an assistant professor in the Department of Molecular Biology and Genetics at Bilkent University. He has more than 30 peer reviewed publications in internationally high ranking journals e.g. Cancer Cell, PNAS, Molecular Systems Biology and Oncogene. His projects are supported by EMBO Installation Grant, FP7 Marie Curie Career Integration Grant, TUBITAK and TUBITAK-CNRS (France). He is also a recipient of TUBA-GEBIP and BAGEP outstanding young scientist awards in 2014.
Asst. Prof. CAGLAR ÇEKİÇ
Dr. Çağlar Çekiç, received his B.S. degree from the Departments of Biology and Biology Education, Middle East Technical University (METU) with honors in 2002. After completing his M.Sc. studies on Biotechnology (2004, METU) and on Immunology (2006, University of Louisville) he received his PhD degree from the University of Louisville, School of Medicine with Dean’s citation in 2009. For his doctoral studies he studied the effects of immunological adjuvants as subunit vaccine additives (Science 2007, J. Biol Chem 2009, J. Immunol 2011). Dr. Çekiç joined as a post-doc fellow to Linden Lab at La Jolla Institute of Allergy and Immunology, University of California San Diego. Among his important post-doctoral work are (1) discovery of a GPCR signaling pathway regulating T cell development and homeostasis (J. Exp. Med. 2013), (2) discovery and characterization of anti-tumor properties of an FDA-approved asthma drug (J. Immunol 2012), (3) identification of cellular targets of novel therapeutics using tissue-specific deletion of target genes (Cancer Research 2014, Science 2015), (4) discovery of a link between cholesterol homeostasis and tumor immunity (Nature Com. 2015). Dr. Çekiç received several grants, awards and fellowships from organizations such as American association of immunologists and American Heart Association, TÜBA, EMBO and TUBİTAK for his sentimental studies and research projects. Dr. Çekiç’s current research interests include understanding the molecular basis of low-toxicity immunomodulation to develop novel vaccine formulations and immunotherapies for cancer.
Asst. Prof. SERKAN GÖKTUNA
Dr. Serkan Göktuna graduated from the Department of Molecular Biology and Genetics at Middle East Technical University in 2003. He obtained his MS degree in Biological Sciences and Bioengineering at Sabancı University in 2005 and his PhD degree in Human Biology at Technical University of Munich in 2010. His PhD work with Prof. Florian Greten earned him 3 CellPress publications and expertise in in vivo mouse models of tumorigenesis. Then he moved to Belgium to do Postdoctoral research on IKK-related kinases in colorectal tumorigenesis under Dr. Alain Chariot’s supervision. Dr. Göktuna is a recipient of the Fonds Leon Fredericq (FLF) research grant and numerous other fellowships during his educational and research years (METU and TÜBİTAK Basic Sciences Scholarship, Sabancı University Graduate Scholarship and Assistantship, TÜBİTAK 2213, WELBIO and FNRS Postdoctoral Fellowships). In March 2015, he started a new assistant professorship position in the Department of Molecular Biology and Genetics at Bilkent University. He has currently 7 peer reviewed publications (and two others under revision) in internationally high ranking journals like Cell, Journal of Experimental Medicine, Cell Reports, Nature Communications, Cell Death and Differentiation, Oncogenesis and Journal of Immunology.
Asst. Prof. MURAT ALPER CEVHER
Since September of 2015, Dr. Murat Alper Cevher is an Assistant Professor at Bilkent University, Department of Molecular Biology and Genetics. He did his undergraduate studies at Hunter College of the City University of New York (CUNY) and graduated in 2004. Later he joined the CUNY Biochemistry Ph.D. program and earned his doctoral degree in 2009. Following that, between 2010-2015 he carried-out his postdoctoral work at the Rockefeller University, a world class institute, in the laboratory of Dr. Robert G. Roeder, a pioneer in the field of transcription. Dr. Cevher is the recipient of the American Cancer Society postdoctoral fellowship (2013), the EMBO Installation Grant (2017), EMBO small grant (2018) and has five peer reviewed publications in high rank journals such as Nature Structural & Molecular Biology, EMBO J, Cancer Research, Wiley’s RNA Review and Nucleic Acids Research of which he is the first author in the first four of them. Dr. Cevher is currently reconstituting the most critical transcriptional co-activator protein complex named the human Mediator. It is one of the largest existing protein complexes in nature and has 30-subunits. He is using the state-of-the-art Multibac baculovirus expression system to carry out this reconstitution. Part of his long-term goal is to build the entire Mediator complex and characterise its interaction surface with activators such as the Estrogen Receptor and structurally-functionally understand the mechanisms behind how these activators activate their target genes that lead to breast cancer.
Asst. Prof. ONUR ÇİZMECİOĞLU
Dr Onur Ҫizmecioḡlu graduated from the Department of Molecular Biology and Genetics at Bilkent University in 2002. He received his Ph.D. degree in 2009 from the German Cancer Research Center (DKFZ) and Heidelberg University in cell biology. During his PhD and a subsequent concise post-doctoral training in the laboratory of Prof. Ingrid Hoffmann, he conducted research in the fields of cell cycle and centrosome duplication. His efforts in the Hoffmann lab culminated in publication of key first and/or second author research articles in prestigious journals including The Journal of Cell Biology, The EMBO Journal, Journal of Biological Chemistry, Journal of Cell Science and Cell Cycle. In order to gain expertise in signal transduction and cancer biology, he joined the lab of Prof. Thomas M. Roberts at Dana-Farber Cancer Institute (DFCI), Harvard Medical School as a research fellow in 2011. His research at DFCI elucidated unique and redundant features of phosphoinositide 3-kinase (PI 3-kinase) isoforms in regulation of signal transduction and carcinogenesis and resulted in two additional publications in Oncogene and eLIFE (and one other under revision). In September 2016, Dr Ҫizmecioḡlu returned to his Alma mater and joined the ranks of the Department of Molecular Biology and Genetics as an assistant professor. His current research is centered on how different members of PI 3-kinases are involved in signaling and cancer.